Abstract

Cell plasticity, changes in cell fate, is crucial for tissue regeneration. In the lung, failure of regeneration leads to diseases, including fibrosis. However, the mechanisms governing alveolar cell plasticity during lung repair remain elusive. We previously showed that PCLAF remodels the DREAM complex, shifting the balance from cell quiescence towards cell proliferation. Here, we find that PCLAF expression is specific to proliferating lung progenitor cells, along with the DREAM target genes transactivated by lung injury. Genetic ablation of Pclaf impairs AT1 cell repopulation from AT2 cells, leading to lung fibrosis. Mechanistically, the PCLAF-DREAM complex transactivates CLIC4, triggering TGF-β signaling activation, which promotes AT1 cell generation from AT2 cells. Furthermore, phenelzine that mimics the PCLAF-DREAM transcriptional signature increases AT2 cell plasticity, preventing lung fibrosis in organoids and mice. Our study reveals the unexpected role of the PCLAF-DREAM axis in promoting alveolar cell plasticity, beyond cell proliferation control, proposing a potential therapeutic avenue for lung fibrosis prevention.

Cell plasticity, changes in cell fate, is involved in tissue regeneration. Here, Kim et al. show that PCLAF-DREAM-driven alveolar cell plasticity is crucial for lung regeneration and targetable as a preventative strategy for lung fibrosis.

Details

Title
PCLAF-DREAM drives alveolar cell plasticity for lung regeneration
Author
Kim, Bongjun 1   VIAFID ORCID Logo  ; Huang, Yuanjian 1 ; Ko, Kyung-Pil 1 ; Zhang, Shengzhe 1 ; Zou, Gengyi 1 ; Zhang, Jie 1 ; Kim, Moon Jong 1   VIAFID ORCID Logo  ; Little, Danielle 2 ; Ellis, Lisandra Vila 2 ; Paschini, Margherita 3 ; Jun, Sohee 1 ; Park, Kwon-Sik 4   VIAFID ORCID Logo  ; Chen, Jichao 2   VIAFID ORCID Logo  ; Kim, Carla 3   VIAFID ORCID Logo  ; Park, Jae-Il 5   VIAFID ORCID Logo 

 The University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, Division of Radiation Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
 The University of Texas MD Anderson Cancer Center, Department of Pulmonary Medicine, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
 Boston Children’s Hospital, Stem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston, USA (GRID:grid.2515.3) (ISNI:0000 0004 0378 8438) 
 University of Virginia, Department of Microbiology, Immunology, and Cancer Biology, Charlottesville, USA (GRID:grid.27755.32) (ISNI:0000 0000 9136 933X) 
 The University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, Division of Radiation Oncology, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776); The University of Texas MD Anderson Cancer Center, Program in Genetics and Epigenetics, Houston, USA (GRID:grid.240145.6) (ISNI:0000 0001 2291 4776) 
Pages
9169
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3120208592
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.